Ascendis Pharma A/S (NASDAQ:ASND) today announced that it has resubmitted its New Drug Application (NDA) for TransCon PTH (palopegteriparatide) for the treatment of adults with hypoparathyroidism to the U.S. Food &
Dr. Saef Izzy's data shows one-month behavioral outcomes improvement in model of intracerebral hemorrhage (hemorrhagic stroke)
Modulation of neuroinflammation by inducing FoxP3+ Tregs appears to have beneficial